疑难病杂志2018，Vol.17Issue(3)：226-229,4.DOI:10.3969/j.issn.1671-6450.2018.03.003
老年慢性阻塞性肺疾病患者合并呼吸机相关性肺炎的病原菌分布变迁及耐药性分析
The pathogenic bacteria distribution and drug resistance analysis of elderly chronic obstructive pulmonary disease with ventilator associated pneumonia patients
摘要
Abstract
Objective To investigate the sputum culture results of the elderly chronic obstructive pulmonary disease (COPD) with ventilator associated pneumonia (VAP) and their corresponding bacterial drug resistance to guide the clinical medication. Methods Selected 98 cases of elderly COPD patients with VAP in intensive care unit of 180th Hospital of PLA from 2015 May to 2017 May,collected sputum specimens after 24h in hospital,and collected 48h sputum of the patients who use mechanical ventilation after 48h after extubation and weaning pneumonia or pneumonia,sputum pathogen culture and drug sensitive test,compared the distribution and drug resistance of the pathogens between the two groups. Results One hundred and ninety-six specimens of 98 cases were Pathogen cultured,151 strains pathogenic bacteria were isolated;Patients admit-ted to hospital with 61 strains bacteria were cultured,the positive rate was 62.2%,occurred after the VAP 90 strains bacteria were cultured,the positive rate was 91.8%, the two groups was significant statistically difference (P<0.05). Pathogenic bacteria drug resistance analysis reveal ordinary beta lactam type with high resistance about pathogenic bacteria. Conclusion The pathogenic of elderly COPD and VAP patients dominated by gram negative bacterial infection, antibiotic resistance is higher,so the drug treatment experience to override common pathogenic bacteria, targeted selection of antibiotics to improve clinical cure rate.关键词
慢性阻塞性肺疾病/呼吸机相关性肺炎/痰培养/细菌耐药Key words
Chronic obstructive pulmonary disease/Breathing machine correlation pneumonia/Sputum culture/Bac-terial drug resistance引用本文复制引用
洪林杰,黄种杰,范洪涛,洪原城..老年慢性阻塞性肺疾病患者合并呼吸机相关性肺炎的病原菌分布变迁及耐药性分析[J].疑难病杂志,2018,17(3):226-229,4.基金项目
2014年南京军区医学科技创新资助项目(14MS093) （14MS093）
